Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: UBS Cuts GlaxoSmithKline To Sell From Neutral

Fri, 25th Jul 2014 09:08

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
UBS CUTS EASYJET PRICE TARGET TO 1930 (2100) PENCE - 'BUY'
----------
JPMORGAN CUTS GLAXOSMITHKLINE PRICE TARGET TO 1370 (1700) PENCE - 'NEUTRAL'
----------
UBS CUTS GLAXOSMITHKLINE TO 'SELL' ('NEUTRAL') - PRICE TARGET 1380 (1500) PENCE
----------
SOCGEN CUTS KINGFISHER PRICE TARGET TO 320 (353) PENCE - 'HOLD'
----------
CITIGROUP CUTS KINGFISHER TO 'NEUTRAL' ('BUY') - TARGET 340 (420) PENCE
----------
DEUTSCHE BANK CUTS KINGFISHER PRICE TARGET TO 430 (460) PENCE - 'BUY'

BERNSTEIN CUTS KINGFISHER PRICE TARGET TO 400 (510) PENCE - 'OUTPERFORM'
----------
NUMIS RAISES REED ELSEVIER PRICE TARGET TO 1130 (1031) PENCE - 'ADD'
----------
MORGAN STANLEY RAISES REED ELSEVIER PRICE TARGET TO 1030 (1000) PENCE. - OVERWEIGHT
----------
BARCLAYS RAISES REED ELSEVIER PRICE TARGET TO 1020 (1005) PENCE. - 'EQUAL WEIGHT'
----------
SOCGEN CUTS PETROFAC TO 'HOLD' ('BUY') - TARGET 1220 (1480) PENCE
----------
DEUTSCHE BANK CUTS BARCLAYS PRICE TARGET TO 275 (300) PENCE - 'BUY'
----------
EXANE BNP RAISES HAMMERSON PRICE TARGET TO 660 (630) PENCE - 'OUTPERFORM'
----------
GOLDMAN RAISES HAMMERSON PRICE TARGET TO 615 (590) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
CREDIT SUISSE CUTS TATE & LYLE PRICE TARGET TO 630 (650) PENCE - 'UNDERPERFORM'
----------
CANACCORD CUTS TATE & LYLE PRICE TARGET TO 640 (660) PENCE - 'HOLD'
----------
UBS CUTS TATE & LYLE PRICE TARGET TO 615 (630) PENCE - 'SELL'
----------
SOCGEN RAISES PROVIDENT FINANCIAL PRICE TARGET TO 2270 (1560) PENCE - 'HOLD'
----------
BERENBERG RAISES PROVIDENT FINANCIAL PRICE TARGET TO 2200 (2050) PENCE - 'HOLD'
----------
BERENBERG RAISES BODYCOTE TO 'BUY' ('HOLD') - TARGET 776 (759) PENCE
----------
CANACCORD CUTS ELECTROCOMPONENTS PRICE TARGET TO 313 (356) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS ELECTROCOMPONENTS PRICE TARGET TO 265 (290) PENCE - 'HOLD'
----------
CANACCORD CUTS LANCASHIRE HLDGS PRICE TARGET TO 670 (690) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS LANCASHIRE HLDGS PRICE TARGET TO 724 (762) PENCE - 'BUY'
----------
JPMORGAN RAISES HOWDEN JOINERY PRICE TARGET TO 420 (416) PENCE - 'OVERWEIGHT'
----------
CITIGROUP RAISES HOWDEN JOINERY GROUP PT TO 370 (365) PENCE - 'NEUTRAL'
----------
Investec Raises AG Barr Price Target To 661p From 645p - ADD
----------
SOCGEN CUTS DRAX GROUP TO 'SELL' ('HOLD') - TARGET 630 PENCE
----------
NUMIS CUTS SPECTRIS TO 'HOLD' ('ADD') - TARGET 2300 PENCE
---------
CREDIT SUISSE CUTS BWIN.PARTY PRICE TARGET TO 88 (99) PENCE - 'UNDERPERFORM'
----------
NUMIS RAISES DE LA RUE TO 'ADD' ('HOLD') - TARGET 845 PENCE
----------
MAIN MARKET AND AIM
----------
BARCLAYS INITIATES TELFORD HOMES WITH 'EQUAL WEIGHT' - TARGET 364.6 PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.



More News
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.